The occurrence rate and disease activity of acute anterior uveitis in ankylosing spondylitis decreased significantly during treatment with golimumab, according to data published in the Journal of Rheumatology.
“The TNF [inhibitor] golimumab was approved for the treatment of AS in 2009, after it was proven to be both effective and safe in a large phase 3 controlled trial,” Rianne E. van Bentum, MD, of the Amsterdam Rheumatology and Immunology Center, and colleagues wrote. “The first reports on the occurrence of [acute anterior uveitis] during [golimumab] treatment seemed
Uncategorized